Creating virtuous cycles in drug development with Rob Freishtat
Description
Rob Freistat, President of Uncommon Cures, discusses how clinical trials are transforming to accelerate drug development and ensure patients receive treatments faster, particularly in the rare disease space.
• Current market uncertainty and investment challenges in biotech, especially for rare disease research
• Approximately two-thirds of clinical trial processes add no value and aren't required by regulations
• Many clinical trial failures occur not because drugs don't work but because trials can't recruit enough patients
• Companies often treat development phases as "islands" rather than planning for commercial success from the beginning
• Rare disease economics require greater efficiency since development costs must be recovered from much smaller patient populations
• Reviving shelved drug candidates represents a potentially valuable opportunity
• Patients should have greater input in trial design and outcome measures that matter to them
• Better communication between sponsors and regulators could significantly improve drug development
________
Reach out to Ivanna Rosendal
Join the conversation on our LinkedIn page
United States
